68Ga-PSMA-617 PET/CT显像与177Lu-EB-PSMA-617放射性配体治疗在腺样囊性癌患者中的初步研究
本初步研究纳入30例病理诊断为腺样囊性癌(ACC)的患者,比较68Ga-PSMA-617与18F-FDG PET/CT的诊断价值,并评估4例接受177Lu-EB-PSMA-617放射性配体治疗(RLT)患者的安全性与疗效。68Ga-PSMA-617对肺外肿瘤检出更多且SUVmax更高,联合18F-FDG可提高总检出效率;PSMA RLT可能是有前景的治疗,值得进一步研究。
要点
- 68Ga-PSMA-617对肺外ACC肿瘤检出数多于18F-FDG(157 vs 141,P=0.016)。
- 联合68Ga-PSMA-617与18F-FDG可检出469个阳性病灶,优于任一单独显像(P<0.001)。
- 2例RLT后显著缓解,另2例复发灶、肺及肝转移摄取降低但骨转移SUVmax升高。
核心结论
- 68Ga-PSMA-617 PET/CT是检测ACC的有价值显像方法,与18F-FDG PET/CT联合可获更高检出效率。
- PSMA RLT可能是ACC有前景的治疗,值得进一步研究。
研究设计与样本
- 初步研究纳入30例病理诊断为ACC的患者,每例均在1周内接受68Ga-PSMA-617与18F-FDG PET/CT。
- 记录并比较PET阳性病灶数目与SUVmax;4例患者接受177Lu-EB-PSMA-617 RLT,剂量约每周期1.85 GBq(50 mCi),最多3个周期。
主要发现
- 68Ga-PSMA-617较18F-FDG检出更多PET阳性肺外肿瘤(157 vs 141,P=0.016),SUVmax更高(8.8±3.6 vs 6.4±4.2,P=0.027)。
- 68Ga-PSMA-617较18F-FDG检出更少PET阳性肺部病灶(202 vs 301,P<0.001),肿瘤SUVmax更低(3.1±3.0 vs 4.2±3.9,P<0.001)。
- 68Ga-PSMA-617与18F-FDG联合检出469个PET阳性病灶,优于各自单独检出(469 vs 359 vs 442,P<0.001)。
- 4例接受PSMA RLT患者中,2例获显著缓解,另2例复发灶、肺及肝转移瘤摄取降低而骨转移SUVmax升高。
局限性
- 原文结论指出PSMA RLT值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. METHODS: Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent 68 Ga-PSMA-617 and 18F-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using 177Lu-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. RESULTS: Compared with 18F-FDG, 68 Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 ± 3.6 vs. 6.4 ± 4.2, P = 0.027). However, 68 Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 ± 3.0 vs. 4.2 ± 3.9, P < 0.001) than 18F-FDG. The combination of 68 Ga-PSMA-617 and 18F-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. CONCLUSIONS: 68 Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with 18F-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. TRIAL REGISTRATION: Diagnosis of Adenoid Cystic Carcinoma on 68 Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264 .
引用
- Wang G, Zhou M, Zang J, et al. A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022. PMID: 35984529. doi:10.1186/s13550-022-00922-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。